The politics of crises in Italy
Italian Political Science Review/Rivista Italiana di Scienza Politica · 2026-03 · 56 (1) · 1-8
DOI: 10.1017/ipo.2026.10090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Italian Political Science Review/Rivista Italiana di Scienza Politica, online erschienen am 08.06.2026. Verfasst von Alessio Scopelliti und 2 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Many people around the globe, including in Europe, have been recently affected by various global crises. In the last 20 years, Europe has experienced the financial crisis, the refugee crisis, COVID-19, increasing extreme weather events associated with climate change, and the breakout of a new war between Russia and Ukraine. This exacerbation of crises has brought increasing scholarly attention to the ‘politics of crises.’ Scholars in political science have examined the politics of crises across a range of domains, such as energy (e.g. Aklin and Urpelainen, 2013; Hancock and Allison, 2020; Bayer et al. , 2025), finance (e.g. Mosley and Singer, 2009; Walter, 2013; Pepinsky, 2014; Copelovitch and Singer, 2020), pandemics (e.g. Worsnop, 2017; Youde, 2018), and migration (e.g. Rudolph, 2003; Hopkins, 2010).
Zitieren
APA
Scopelliti, A., Kalatzi-Pantera, D., & Grechanaya, T. (2026). The politics of crises in Italy. Italian Political Science Review/Rivista Italiana di Scienza Politica, 56(1), 1-8. https://doi.org/10.1017/ipo.2026.10090
Vancouver
Scopelliti A, Kalatzi-Pantera D, Grechanaya T. The politics of crises in Italy. Italian Political Science Review/Rivista Italiana di Scienza Politica. 2026;56(1):1-8. doi:10.1017/ipo.2026.10090
BibTeX
@article{Scopelliti2026,
author = {Scopelliti, Alessio and Kalatzi-Pantera, Dafni and Grechanaya, Tamara},
title = {The politics of crises in Italy},
journal = {Italian Political Science Review/Rivista Italiana di Scienza Politica},
year = {2026},
volume = {56},
number = {1},
pages = {1--8},
doi = {10.1017/ipo.2026.10090}
}
EUVIMED